Myriad Genetics, Inc. (MYGN)

Market Cap	1.39B
Revenue (ttm)	823.60M
Net Income (ttm)	-116.00M
Shares Out	91.04M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	146.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	660,564
Open	14.93
Previous Close	15.00
Day's Range	14.74 - 15.33
52-Week Range	14.74 - 29.30
Beta	1.94
Analysts	Buy
Price Target	26.64 (+74.12%)
Earnings Date	Nov 7, 2024

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or sus...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 5, 1995
• Employees: 2,700
• Stock Exchange: NASDAQ
• Ticker Symbol: MYGN
• Website: https://www.myriad.com

Financial Performance

In 2023, Myriad Genetics's revenue was $753.20 million, an increase of 11.03% compared to the previous year's $678.40 million. Losses were -$263.30 million, 135.1% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price forecast is $26.64, which is an increase of 74.12% from the latest price.

Price Target

$26.64

(74.12% upside)

Analyst Consensus: Buy